Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Scholar Rock Holding ( (SRRK) ) has shared an update.
On October 10, 2025, Scholar Rock Holding Corporation was informed by Novo Nordisk that the U.S. Food and Drug Administration has classified the inspection of Catalent Indiana, LLC as ‘official action indicated’ following a Form FDA 483 issued on July 14, 2025. This classification could have implications for Scholar Rock’s operations and its stakeholders, as it suggests regulatory concerns at a facility owned by Novo Nordisk.
The most recent analyst rating on (SRRK) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page.
Spark’s Take on SRRK Stock
According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.
Scholar Rock’s overall stock score reflects significant challenges due to financial underperformance, including a lack of revenue and ongoing losses. Despite these issues, positive strides in its SMA program and strategic leadership changes indicate potential for future growth. Mixed technical indicators and a weak valuation further moderate the outlook.
To see Spark’s full report on SRRK stock, click here.
More about Scholar Rock Holding
Average Trading Volume: 2,287,936
Technical Sentiment Signal: Buy
Current Market Cap: $3.79B
For detailed information about SRRK stock, go to TipRanks’ Stock Analysis page.